If the government is sincere about boosting the biotechnology sector, it needs to cut the red tape stifling development, industry insiders said yesterday.
"Taiwan's government requires new drugs, even locally developed ones, to obtain approval from at least one other country before applying for domestic permission," said Chen Kuang-chi (
"Such a requirement seems to indicate that the government lacks confidence in domestically developed pharmaceutical products," Chen said.
Maywufa Bio-Pharmaceutical is a Taipei-based company with businesses covering pharmaceutical research and development, drug distribution and drugstore chains. Its revenues reached NT$3.5 billion last year.
Chen said the industry hopes the regulatory authorities will abolish such unreasonable regulations for the sake of nurturing the nation's developing biotech industry.
The government said in 2002 that it would spare no efforts to promote the biotech industry, making it one of the key sectors of the government's "Two Trillion, Two Star" (兩兆雙星) investment plan for the next 10 years. Other sectors include semiconductors, flat-panel displays and digital content industries.
Annual revenues in the fledgling biotech industry rose 13 percent to NT$125.6 billion last year from NT$110.9 billion the previous year, according to figures provided by the Biotechnology & Pharmaceutical Industries Program Office (BPIPO) under the Ministry of Economic Affairs.
The government plans to pour NT$150 billion into the sector by 2006, hoping the investment can help boost annual revenues 25 percent a year to NT$250 billion by 2006, said William Chung (
Taiwan is one of several Asian countries where international biotech companies are considering possible business opportunities.
"Asia, with a population of 3.23 billion, is a market of huge potential for the industry," said Jonathan Watters, senior vice president of BioPro Pharmaceutical Inc, a Waikanae, New Zealand-based pharmaceutical R&D and marketing company.
Asia's market, excluding Japan, could be worth US$30 billion next year, with China making up 34 percent of the total, Watters said, and Taiwan 14 percent.
However, the variation in regulations between countries in the region make it more costly for companies to get drugs approved.
"One decision [for new drugs] can then become effective in 23 countries in the European Union, starting from this July," Watters said.
The industry, he added, was hoping Asian countries could harmonize regulatory requirements or recognize drugs approved elsewhere.
This is unlikely, even in the next few decades, as such a move would reduce countries' autonomy, said Chen Chei-hsiang (陳啟祥), director of BPIPO.
In the absence of regulatory harmonization, companies could encourage mutual recognition of their drugs by undertaking clinical trials for new drugs, a necessary process ahead of application, in several countries at the same time, Maywufa's Chen said.
"The result of scientific experiments would speak for us," Chen said. "And we expect cross-border efforts by the private sector to stimulate change in the official sector."
Intel Corp chief executive officer Lip-Bu Tan (陳立武) is expected to meet with Taiwanese suppliers next month in conjunction with the opening of the Computex Taipei trade show, supply chain sources said on Monday. The visit, the first for Tan to Taiwan since assuming his new post last month, would be aimed at enhancing Intel’s ties with suppliers in Taiwan as he attempts to help turn around the struggling US chipmaker, the sources said. Tan is to hold a banquet to celebrate Intel’s 40-year presence in Taiwan before Computex opens on May 20 and invite dozens of Taiwanese suppliers to exchange views
Application-specific integrated circuit designer Faraday Technology Corp (智原) yesterday said that although revenue this quarter would decline 30 percent from last quarter, it retained its full-year forecast of revenue growth of 100 percent. The company attributed the quarterly drop to a slowdown in customers’ production of chips using Faraday’s advanced packaging technology. The company is still confident about its revenue growth this year, given its strong “design-win” — or the projects it won to help customers design their chips, Faraday president Steve Wang (王國雍) told an online earnings conference. “The design-win this year is better than we expected. We believe we will win
Chizuko Kimura has become the first female sushi chef in the world to win a Michelin star, fulfilling a promise she made to her dying husband to continue his legacy. The 54-year-old Japanese chef regained the Michelin star her late husband, Shunei Kimura, won three years ago for their Sushi Shunei restaurant in Paris. For Shunei Kimura, the star was a dream come true. However, the joy was short-lived. He died from cancer just three months later in June 2022. He was 65. The following year, the restaurant in the heart of Montmartre lost its star rating. Chizuko Kimura insisted that the new star is still down
While China’s leaders use their economic and political might to fight US President Donald Trump’s trade war “to the end,” its army of social media soldiers are embarking on a more humorous campaign online. Trump’s tariff blitz has seen Washington and Beijing impose eye-watering duties on imports from the other, fanning a standoff between the economic superpowers that has sparked global recession fears and sent markets into a tailspin. Trump says his policy is a response to years of being “ripped off” by other countries and aims to bring manufacturing to the US, forcing companies to employ US workers. However, China’s online warriors
RSS